|
Tuesday,
March 25
7:00am Registration
(Open until
5:30pm)
8:00 Plenary Keynote Introduction
 Harry
Glorikian, Managing Partner, Scientia Advisors
8:15 Diagnosing the Disease: Disruptive
Innovation in Healthcare
Clayton M. Christensen, DBA, Robert and
Jane Cizik Professor of Business Administration, Harvard Business
School
In the absence of the
ability to precisely defi ne a disease, the care of patients is
best undertaken by highly skilled professionals, whose intuition
is based on deep experience. This describes the history of health
care, and we call this the practice of intuitive medicine.
Molecular biology holds the promise of transforming medical
practice into a new phase that we call precision medicine. It
promises to dramatically reduce cost and increase the predictable
effectiveness of therapy.
9:45 Coffee Break
10:15am ・1:15pm Morning
Pre-Conference Short Course*
|
Recommended Short
Course*
|
|
(SC5) IMMUNOLOGICAL BIOMARKERS:
"HOW TO" AND THREE CASE STUDIES
Moderator: Eric Wakshull, Ph.D., Senior
Scientist/Group Leader, Development Sciences, Genentech Inc.
Immunological Biomarkers and Methods
Annie De Groot, M.D., Chief Executive
Officer, EpiVax, Inc. and Brown University
Case Study: GDNF
Michael Moxness, Ph.D., Principal
Scientist Clinical Immunology, Amgen Inc.
Case Study: DR 0701
Karin Cederbrandt, Ph.D., Molecular
Toxicology, AstraZeneca
Case Study: Alpha-interferon
Maxygen (invited)
Panel Discussion with
Q&A
*Separate Registration Required
|
1:15 Lunch on Your Own
2:30 - 5:30 Afternoon Pre-Conference
Short Course*
|
Recommended Short
Course*
|
|
(SC8) MODELS FOR EVALUATING DRUG-DRUG
INTERACTION POTENTIAL IN PRECLINICAL DEVELOPMENT
This course will cover:
-
An overview of drug-drug interactions
from the clinical perspective, withdrawn drugs and the overall
impact on development
-
CYP inhibition and induction methods
and in vitro/in vivo correlations
-
Transporter models and in vitro/in
vivo correlations
More Short Courses:
(SC1) BIOMARKERS ARE US: INTERACTIVE
SHORT COURSE ON HOW BIOMARKERS WILL IMPACT THE FIELD OF ONCOLOGY
(SC2) THE CHALLENGE OF THE BLOOD-BRAIN
BARRIER A MEDICINAL CHEMISTRY PERSPECTIVE
(SC3) ADMET CASE STUDIES FROM A
MEDICINAL CHEMISTRY PERSPECTIVE
(SC4) THE EPIGENETIC STEM CELL
SIGNATURE
(SC6) CIRCULATING TUMOR CELLS
(SC7) CANCER STEM CELLS
(SC10) Navigating through Indian
Regulatory Terra Incognita: A Hands-on Workshop
*Separate Registration
Required
|
|
English
Traditional Chinese
Simplified Chinese
Korean